VIDEO: Longer follow-up on CAR T-cell therapy for DLBCL shows durability and tolerability
In this video, Brian T. Hill, MD, PhD, discusses results of the phase 2 PILOT study of lisocabtagene maraleucel as second-line therapy for relapsed/refractory diffuse large B-cell lymphoma.
An update of the study presented at ASH Annual Meeting and Exhibition evaluated longer-term data on older patients who were not deemed to be transplant candidates and who received the chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb).
"What we see with longer follow-up is durability of disease control and general tolerability of this approach," Hill, director of the lymphoid malignancies program at ] Cleveland Clinic, said.
"We're now getting into the era where we have many different options for relapsed/refractory diffuse large B-cell lymphoma," Hill said.
Reference:
- Sehgal A, et al. Lisocabtagene maraleucel as second-line therapy for R/R large B-Cell lymphoma in patients not intended for hematopoietic stem cell transplant: Final analysis of the phase 2 PILOT study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews